Alloy Therapeutics, a Boston based biotechnology ecosystem company, has entered into a definitive agreement to acquire deepCDR Biologics, a privately held Basel based developer of deep learning technology for antibody discovery and optimisation. Alloy will
Tags :Timothy Woodtli
GlycoEra has successfully completed a CHF 45 million Series A financing round, co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics, from which GlycoEra was spun-out, also participated in this round. GlycoEra’s
Vischer acted as legal counsel for Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), on the closing of its CHF 18 million seed round. The financing was led
The team included partner Matthias Staehelin and associate Timothy Woodtli (both Corporate).
The team included partner Christian Wyss (Life Sciences - pictured), associate Timothy Woodtli (Corporate/M&A), associate Francesca Pesenti (Corporate/M&A), and associate Gian Geel (Employment).
